The cardiovascular effects of the antihypertensive drug debrisoquin: A contribution to the pharmacology of chronic treatment. III. Absence of adrenergic degeneration after 8-week administration to dogs.
D000311:Adrenal Glands / Q000187:drug effects; D000320:Adrenergic Fibers / Q000187:drug effects*; D000818:Animals; D002319:Cardiovascular System / Q000187:drug effects*; D003647:Debrisoquin / Q000494:pharmacology*; D004285:Dogs; D004299:Dopamine beta-Hydroxylase / Q000378:metabolism; D005725:Ganglia, Autonomic / Q000032:analysis; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects; D009206:Myocardium / Q000032:analysis; D009410:Nerve Degeneration; D009638:Norepinephrine / Q000032:analysis; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism; D014649:Vas Deferens / Q000187:drug effects
D007546:Isoquinolines; D014446:Tyrosine 3-Monooxygenase; D004299:Dopamine beta-Hydroxylase; D003647:Debrisoquin; D009638:Norepinephrine